Stem cells from amniotic fluid tested for progressive MS – but trial pulled

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-60 years. * Diagnosed with primary or secondary progressive MS according to the 2017 revised McDonald criteria. * Expanded Disability Status Scale (EDSS) of 3.0 to 8.0 with at least one functional scale that is not vision or sensory or brainstem or cognitive or bowel/bladder that is scoring 3.0 or greater. * Clinically stable as determined by their neurologist for the past 6 months. * On no disease-modifying therapy (DMT) for at least 6 months, or on the same DMT for at least 6 months before study entry. * Can give informed consent. * Women of child-bearing age must practice adequate contraception techniques in the eye of the investigator and continue to do so during the study period. * Must be a good candidate, known for compliance for example, in the opinion of the investigators. Exclusion Criteria: * Participation in another clinical trial within the last 30 days. * Severe allergic reactions to any component of the study treatments. * Significant comorbidities. * Active infections or malignancies. * History of a malignancy within the past two years except for skin cancer that has been excised and controlled with only surgical treatment, not requiring chemotherapy or radiotherapy. * Any medical condition that the investigator deems as unsuitable with therapy. * Prior organ, tissue, or stem cell transplant or cell therapy within 3 years of study entry * A diagnosis of a progressive neurological disorder other than multiple sclerosis. * Inability to have an MRI scan. * Inability to have a lumbar puncture, for example severe bleeding diathesis. * Pregnant or breastfeeding or intention to become pregnant during the study. * The results of the following laboratory results deemed suitable by the investigators: CBC with diff, CMP, INR, aPTT, Hepatitis C serology, HIV serology, RPR.